| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 351.54 | 11.7% |
| Total Income | 356.02 | 11.9% |
| Expenditure | 313.35 | 12.4% |
| PBT | 42.68 | 8.6% |
| Net Profit | 31.02 | 4.9% |
| OPM | 14.82% | 0.33pp |
| NPM | 8.71% | 0.59pp |
| EPS | 5.42 | 4.8% |
Innova Captab Reports 19% YoY Revenue Growth in Q1 FY26, EBITDA Grows 28%
07 Aug 2025 · 7 Aug 2025, 06:02 pm
Summary
Innova Captab Limited, a leading pharmaceutical company, reported strong results for Q1 FY26 with Revenue from Operations at 351.5 crore and EBIDTA at 56.6 crore. The company registered a YoY revenue growth of 19% and EBITDA growth of 28%.
Key Highlights
- 1
Revenue from Operations recorded robust growth of 19% year-on-year, reaching 351.5 crore in Q1 FY26
- 2
Consolidated EBITDA stood at 56.6 crore vs 44.3 crore in Q1 FY25 signifying solid YoY growth of 28%
- 3
EBITDA margins improved to 16.1% vs 15.1% in Q1 FY25
- 4
PAT increased by 5% YoY to 31.0 crore
- 5
Newly commissioned facility in Jammu gained momentum during the quarter
- 6
Reorganized business areas into two focused verticals: CDMO and Branded Generics
Management Comments
Mr. Vinay Lohariwala
The first quarter has provided us with a strong and confident start to the financial year 2026. We delivered solid growth, reflected in both a healthy expansion of our topline and a notable improvement in operating profitability. We continued to make steady progress on our strategic initiatives, in line with our plans. Our newly commissioned facility in Jammu gained momentum during the quarter, and we expect this traction to accelerate in the coming quarters and beyond. In a pivotal move, we have reorganized our business areas into two focused verticals: CDMO and Branded Generics to synchronize with our strategic vision.
Informational and educational content only. Not investment advice.